Methods and effects of injection of salvianolic acid B combined with triamcinolone acetonide in the treatment of oral submucous fibrosis

doi:10.19439/j.sjos.2017.02.013

Abstract

Abstract: PURPOSES: To introduce the methods of triamcinolone acetonide (TA) and salvianolic acid B(SA-B) intralesional injection in the treatment of oral submucous fibrosis and evaluate the treatment effects. METHODS: TA combined with SA-B were consecutively applied intralesionally 1 time weekly for 30 times. The technique of intralesional injection was that syringe needle be emptied into submucous tissues 1 cm posterior to the corner of oral cavity running from the front to retromolar area by pushing the injection, then the syringe needle retained to the original point and upward from the front to retromolar area by pushing the injection, finally the syringe needle returned to the starting point and downward from the front to retromolar area by pushing the injection. Mouth opening, the color change of the buccal mucosa and the increase of capillary vessels as determined by degree I-IV visual analog scale were evaluated at 12, 24, and 36 month. The data were analyzed with SPSS 21.0 software package. RESULTS: One hundred and fourteen subjects fulfilled the study without obvious adverse reactions. After treatment for 36 months , the net gain in mouth opening of the early stage group,middle stage group and advanced stage group was (12.0±1.2) mm, (14.5±2.4) mm and (15.5±1.5) mm, respectively. The response rate of color change of the buccal mucosa and the increase of capillary vessels in early stage group, middle stage group and advanced stage group after treatment for 36 months was 100%, 94.7% and 90.7%, respectively. CONCLUSIONS: Triamcinolone acetonide and salvianolic acid B intralesional injection is effective in the treatment of oral submucous fibrosis.

Key words: Oral mucous disease, Oral submucous fibrosis, Triamcinolone acetonide, Salvianolic acid B

CLC Number:

R781.5

XIAO Yi-cai, JIAN Xin-chun, ZHENG Lian, ZHOU Chao, DU Yong-xiu, ZHOU Ting, WANG Bin-ping. Methods and effects of injection of salvianolic acid B combined with triamcinolone acetonide in the treatment of oral submucous fibrosis[J]. Shanghai Journal of Stomatology, 2017, 26(2): 188-192.

References

[1] 翦新春, 沈子华, 刘蜀凡. 口腔黏膜下纤维性变（附2例报告）[J]. 临床口腔医学杂志, 1985, 1(1): 12-13.
[2] Tang JG, Jian XF, Gao ML, et al. Epidemiological survey of oral submucous fibrosis in Xiangtan City, Hunan Province, China [J]. Community Dent Oral Epidemiol, 1997, 25(2): 177-180.
[3] Yang YH, Lee HY, Tung S, et al. Epidemiological survey of oral submucous fibrosis and leukoplakia in aborigines of Taiwan [J]. J Oral Pathol Med, 2001, 30(4): 213-219.
[4] Rajendran R. Oral submucous fibrosis: etiology, pathogenesis, and future research [J]. Bull World Health Organ, 1994, 72(6): 985-996.
[5] Liao PH, Lee TL, Yang LC, et al. Adenomatous polyposis coli gene mutation and decreased wild-type p53 protein expression in oral submucous fibrosis: a preliminary investigation [J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2011, 92(2): 202-207.
[6] Ariyawardana A, Athukorala AD, Arulanandam A. Effect of betel chewing, tobacco smoking and alcohol consumption on oral submucous fibrosis: a case-control study in Sri Lanka [J]. J Oral Pathol Med, 2006, 35(4): 197-201.
[7] IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Betel-quid and areca nut chewing and some areca-nut derived nitrosamins [J]. IARC Monogr Eval Carcinog Risks Hum, 2004, 85: 1-334.
[8] 胡延佳, 翦新春, 刘斌杰, 等. 2种基因芯片数据分析软件在口腔黏膜下纤维化差异表达基因分析中的应用[J]. 中华口腔医学杂志, 2008, 43(3): 168-171.
[9] Li N, Jian X, Hu Y, et al. Discovery of novel biomarkers in oral submucous fibrosis by microarray analysis [J]. Cancer Epidemiol Biomarkers Prev, 2008, 17(5): 2249-2259.
[10] 翦新春. 口腔黏膜下纤维性变及癌变机理研究进展（述评）[J]. 中国医师杂志, 2015, 17(9): 1281-1285.
[11] Canniff JP, Harvey W, Harris M. Oral submucous fibrosis: its pathogenesis and management [J]. Br Dent J, 1986, 160(12): 429-434.
[12] Huang IY, Wu CF, Shen YS, et al, Importance of patient's cooperation in surgical treatment for oral submucous fibrosis [J]. J Oral Maxillofac Surg, 2008, 66(4): 699-703.
[13] Liu P, Hu YY, Liu C, et al. Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B [J]. World J Gastroenterol, 2002, 8(5): 679-685.
[14] 中华口腔医学会口腔黏膜病专业委员会. 口腔黏黏膜下纤维性变的诊断标准（试行稿）[J]. 中华口腔医学杂志, 2009, 44(30): 130-131.
[15] Tilakaratne WM, Klinikowski MF, Saku T, et al. Oral submucous fibrosis: review on aetiology and pathogenesis [J]. Oral Oncol, 2006, 42(6): 561-568.
[16] Rajalalitha P, Vali S. Molecular pathogenesis of oral submucous fibrosis-a collagen metabolic disorder[J]. J Oral Pathol Med, 2005, 34(6): 321-328.
[17] Gupta S, Reddy MV, Harinath BC. Role of oxidative stress and antioxidants in aetiopathogenesis and management of oral submucous fibrosis[J]. Indian J Clin Biochem, 2004, 19(1): 138-141.
[18] Haqueous MF, Harris M, Meghji S, et al. Immunolocalization of cytokines and growth factors in oral submucous fibrosis [J]. Cytokine, 1998, 10(9): 713-719.
[19] Singh M, Niranjan HS, Mehrotra R, et al. Efficacy of hydrocortisone acetate/hyaluronidase vs triamcinolone acetonide/ hyaluronidase in the treatment of oral submucous fibrosis [J]. Indian J Med Res, 2010, 131: 665-669.
[20] Wang X, Morris-Natschke SL, Lee KH. New developments in the chemistry and biology of the bioactive constituents of Tan-shen [J]. Med Res Rev, 2007, 27(1): 133-148.
[21] Li LN. Biologically active components from traditional Chinese medicines [J]. Pure Appl Chem, 2008, 70(3): 547-554.
[22] Liu P, Liu CH, Wang HN, et al. Effect of salvianolic acid B on collagen production and mitogen-activated protein kinase activity in rat hepatic stellate cells[J]. Acta Phamacol Sin, 2001, 23(8): 733-738.
[23] Lv Z, Xu L. Salvianolic acid B inhibits ERK and p38 MAPK Signaling in TGF-B1 stimulated human hepatic stellate cell line (LX-2) via distinct pathways[J]. Evid Based Complement Alternat Med, 2012, 20（2）: 96-128.
[24] Wang SX, Hu LM, Gao XM, et al. Anti-inflammatory activity of salvianolic acid B in microglia contributes to its neuroprotective effect [J]. Neurochem Res, 2010, 35(7): 1029-1037.
[25] Chen T, Liu W, Chao X. et al. Salvianolic acid B attenuates brain damage and inflammtion after traumatic brain injury in mice[J]. Brain Res Bull, 2011, 84(2): 163-168.